Literature DB >> 1277722

Studies on digitalis. VI. The effect of heparin on serum protein binding of digitoxin and digoxin.

L Storstein, H Janssen.   

Abstract

The aim of the present study was to investigate the nature of the previously reported changes in the serum protein binding of digitoxin and digoxin in uremic patients under treatment with hemodialysis. Kinetic studies on protein binding during hemodialysis showed that the free fraction of digitoxin rose from 2.6% to 6.9% after 5 min of hemodialysis and remained elevated during the dialyzing period. Free digoxin rose from hemodialysis and remained elevated during the dialyzing period. Free digoxin rose from 78.3% to 87.1% during the same period. In vitro hemodialysis experiments showed that such changes occurred only in vivo. Injection of heparin (5,000 IU) to control subjects produced similar kinetic changes in the protein binding of digitoxin and digoxin. Free fatty acids changed in the same way. These results indicate that the heparin-induced release of free fatty acids causes displacement of digitoxin and digoxin from their albumin-binding sites. Patients on hemodialysis have lower serum levels of digitoxin and cardioactive metabolites (mean, 8.9 ng/ml) than control patients (mean, 16.7 ng/ml) (p less than 0.005) on similar doses (mean, 0.085 mg/day). They should be maintained on the same digotoxin doses as uremic and control patients, but serum digitoxin levels should be adjusted to 10 to 15 ng/ml in hemodialysis patients compared to 15 to 25 ng/ml in uremic patients and in patients with normal renal function.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277722     DOI: 10.1002/cpt197620115

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

Review 1.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

2.  Clinical pharmacokinetics of digitoxin.

Authors:  D Perrier; M Mayersohn; F I Marcus
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

3.  Potential applications of free drug level monitoring in cardiovascular therapy.

Authors:  R L Woosley; L A Siddoway; K Thompson; I Cerskus; D M Roden
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 5.  Effect of cardiopulmonary bypass on the pharmacokinetics of drugs.

Authors:  F O Holley; K V Ponganis; D R Stanski
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

6.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

7.  Heparin administration increases plasma warfarin binding in man.

Authors:  P A Routledge; T D Bjornsson; B B Kitchell; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of digoxin.

Authors:  E Iisalo
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 9.  Protein binding of cardiac glycosides in disease states.

Authors:  L Storstein
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

10.  Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.

Authors:  A Johnston; J A Henry; S J Warrington; N A Hamer
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.